Therapy
Biotechnology
Health

Intellia Therapeutics

$14.56
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.43 (2.98%) Today
-$0.29 (-1.95%) After Hours

Why Robinhood?

You can buy or sell NTLA and other stocks, options, ETFs, and crypto commission-free!

About

Intellia Therapeutics, Inc. engages in the development of gene editing-based therapies. It provides scientific expertise, clinical development, and intellectual property position to unlock broad therapeutic applications of CRISPR or Cas9 genome editing and develop a potential new drug class. Read More The company was founded by Andrew May, Luciano Marraffini, Rodolphe Barrangou, Nessan Bermingham, Rachel Haurwitz, Erik Sontheimer, Jennifer Doudna, and Derrick Rossi in May 2014 and is headquartered in Cambridge, MA.

Employees
211
Headquarters
Cambridge, Massachusetts
Founded
2014
Market Cap
655.81M
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
672.84K
High Today
$14.88
Low Today
$14.32
Open Price
$14.42
Volume
195.91K
52 Week High
$32.95
52 Week Low
$11.03

Collections

Therapy
Biotechnology
Health
Medical
Technology
2016 IPO
US
North America

News

Yahoo FinanceMay 9

Is Intellia Therapeutics, Inc. A Good Stock To Buy?

"October lived up to its scary reputation—the S&P 500 falling in the month by the largest amount in the last 40 years, the only worse Octobers being '08 and the Crash of '87. For perspective, there have been only 5 occasions in those 40 years when the S&P 500 declined by greater than 20% from peak to trough.

548
Simply Wall StMay 4

Need To Know: Intellia Therapeutics, Inc. (NASDAQ:NTLA) Insiders Have Been Buying Shares

Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! We often see insiders buying up shares in companies that perform well over the long term. Unfortunately, there are also plenty of examples of share prices declining precipitously after insiders have sold shares. So before you buy or sell Intellia Therapeutics, Inc. (NASDAQ:NTLA), you may well want to know whether insiders have been buying or selling. What Is Insider Selling? Most in...

497
The Motley FoolMay 2

Intellia Therapeutics, Inc. (NTLA) Q1 2019 Earnings Call Transcript

180

Earnings

-$0.61
-$0.55
-$0.49
-$0.43
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Estimated
Actual
Expected Jul 31, Pre-Market

Popular Stocks

All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.